Blog

Nov 4, 2023

Type 2 diabetes: New GLP-1 agonist may lead to long-lasting treatment

Posted by in category: biotech/medical

These risks may be amplified with longer-lasting treatments, as Dr. Shafipour cautioned:

“Higher levels of GLP-1 are associated with more gastrointestinal side effects, including nausea, acid reflux, constipation, and bloating, which in some individuals, could be a cause for discontinuation of the drug.”

However, she added: “If this is not a side effect due to this novel technology, this could be a great advantage over the current GLP-1 receptor agonists.”

Comments are closed.